Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

Meta-Analysis of Chemotherapy With Irinotecan or Oxaliplatin-Involved Regimen for Untreated Metastatic Advanced Colorectal Cancer

(2010) Luhong Zhuang et al.   ONCOLOGY RESEARCH

Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting

(2009) F. Roila et al.   ANNALS OF ONCOLOGY

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

(2009) Wichit Arpornwirat et al.   CANCER

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

(2009) Jørn Herrstedt et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

(2009) Steven M Grunberg et al.   LANCET ONCOLOGY

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER

FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

(2008) Saima Sharif et al.   CANCER INVESTIGATION

Chemotherapy-Induced Nausea and Vomiting

(2008) Paul J. Hesketh   NEW ENGLAND JOURNAL OF MEDICINE